Abraxis Bioscience LLC. dismissed complaint against SPARC
Sun Pharma Advanced Research Company Ltd. (SPARC) (Reuters: SPRC.BO, Bloomberg: SPADV IN, NSE: SPARC, BSE: 532872) today announced that Abraxis Bioscience LLC. has dismissed the patent infringement complaint filed against SPARC regarding SPARC's New Drug Application for PICS (Paclitaxel Injection Concentrate for Suspension).
"We are very pleased that Abraxis Bioscience LLC. has withdrawn its infringement claims paving the way for a successful launch as and when we receive necessary regulatory approvals," said Anil Raghavan, CEO of SPARC.
SPARC will also inform the USFDA of the dismissal of the complaint to vacate the 30-month stay.
Shares of SUN PHARMA ADVANCED RESEARCH COMPANY LTD. was last trading in BSE at Rs.153.7 as compared to the previous close of Rs. 156.4. The total number of shares traded during the day was 190346 in over 3321 trades.
The stock hit an intraday high of Rs. 161.3 and intraday low of 151. The net turnover during the day was Rs. 29913491.